Kiora Pharmaceuticals, Inc.
(NASDAQ : EYEG)

( )
EYEG PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Major
symbolcompany%chnglast%shortavg$volume
JNJJohnson & Johnson 1.59%182.510.7%$1411.48m
MRKMerck & Co., Inc. 1.39%93.280.7%$1241.52m
PFEPfizer Inc. 3.21%51.700.9%$1234.19m
BMYBristol-Myers Squibb Co. 1.67%78.991.0%$1137.41m
LLYEli Lilly & Co. 4.15%325.691.1%$1136.04m
ABBVAbbVie, Inc. 2.07%152.551.9%$1019.26m
AZNAstraZeneca Plc 3.80%66.901.0%$452.09m
SGENSeagen Inc. 3.06%179.335.7%$326.01m
GSKGSK Plc 2.20%43.690.2%$297.44m
TPTXTurning Point Therapeutics, Inc. 0.03%75.170.0%$291.93m
SIGASIGA Technologies, Inc. -0.46%13.040.0%$219.68m
MRTXMirati Therapeutics, Inc. 3.45%68.161.6%$199.41m
HZNPHorizon Therapeutics Plc 2.68%85.135.4%$182.59m
NVSNovartis AG 3.62%84.820.2%$167.75m
BHVNBiohaven Pharmaceutical Holding Co. Ltd. -0.14%144.000.0%$147.86m

Company Profile

Kiora Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes KIO-301, which is designed to restore vision in patients with inherited and age-related degenerative retinal disease, KIO-101 for patients with Ocular Presentation of Rheumatoid Arthritis, KIO-201 for patients undergoing PRK surgery for corneal wound repair after refractive surgery, and KIO-102. The company was founded in 1998 and is headquartered in Salt Lake City, UT.